{"id":"NCT01387607","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A Study For Pregabalin In Patients With Fibromyalgia","officialTitle":"A 14-week, Randomized, Double-blind Placebo-controlled Study For Pregabalin In Subjects With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02-06","primaryCompletion":"2016-10-31","completion":"2016-10-31","firstPosted":"2011-07-04","resultsPosted":"2018-07-30","lastUpdate":"2021-01-28"},"enrollment":343,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"pregabalin","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Pregabalin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and tolerability of pregabalin compared with placebo for management of fibromyalgia in adults.","primaryOutcome":{"measure":"Change From Baseline in Endpoint Mean Pain Score During the Double-blind Treatment Period at Week 14","timeFrame":"Baseline, Week 14","effectByArm":[{"arm":"Pregabalin","deltaMin":-2.01,"sd":0.148},{"arm":"Placebo","deltaMin":-1.28,"sd":0.15}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":22,"countries":["China"]},"refs":{"pmids":["33658841"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081241&StudyName=A%20Study%20For%20Pregabalin%20In%20Patients%20With%20Fibromyalgia%20"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":170},"commonTop":["Dizziness","Somnolence","Headache","Upper respiratory tract infection"]}}